170 related articles for article (PubMed ID: 28388749)
1. [Biosimilars in Rheumatologie: a New Challenge?].
Kekow J
Dtsch Med Wochenschr; 2017 Apr; 142(7):521-524. PubMed ID: 28388749
[No Abstract] [Full Text] [Related]
2. Biosimilars: how similar?
Strand V; Cronstein B
Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
[TBL] [Abstract][Full Text] [Related]
3. Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases.
Schulze-Koops H
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv1-iv3. PubMed ID: 28903541
[No Abstract] [Full Text] [Related]
4. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
5. Comment on: The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Müller-Ladner U
Acta Reumatol Port; 2014; 39(1):7-8. PubMed ID: 24811455
[No Abstract] [Full Text] [Related]
6. Biosimilars, a new era in rheumatology in Spain.
Díaz-González F; Bustabad-Reyes S
Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):131-132. PubMed ID: 32063503
[No Abstract] [Full Text] [Related]
7. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
8. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
[No Abstract] [Full Text] [Related]
9. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
10. Update on biosimilars in rheumatology.
Rischin A; Östör AJ
Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
Schaeverbeke T; Pham T; Richez C; Wendling D
Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
[No Abstract] [Full Text] [Related]
12. Biosimilars: clinical interpretation and implications for drug development.
Mysler E
Curr Rheumatol Rep; 2015 Feb; 17(2):8. PubMed ID: 25618574
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in rheumatic diseases.
Hajji R
Int J Clin Pract; 2021 Mar; 75(3):e13709. PubMed ID: 32940382
[No Abstract] [Full Text] [Related]
14. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
15. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars vs originators: Are they the same?
Sarzi-Puttini P; Marotto D; Caporali R; Galeazzi M; Atzeni F; Hamar A; Soós B; Szekanecz Z
Autoimmun Rev; 2019 Dec; 18(12):102404. PubMed ID: 31639517
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
18. Potential for biosimilars in rheumatology in Africa.
Abu-Zaid MH; Adebajo A; El Miedany Y
Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
[TBL] [Abstract][Full Text] [Related]
19. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars approved for treatment of inflammatory rheumatological diseases.
Mahler SM; Wardiana A; Jones ML; de Bakker CJ; Graham GG; Howard CB
Int J Rheum Dis; 2016 Nov; 19(11):1043-1048. PubMed ID: 28032957
[No Abstract] [Full Text] [Related]
[Next] [New Search]
